Our Alzheimer's drug was not a com­plete bust, says vTv; Xtalpi rais­es $46M more for AI drug dis­cov­ery en­gine

→ Still re­cov­er­ing from the ham­mer­ing it took on the fail­ure of its Alzheimer’s drug, lit­tle vTv $VTVT is push­ing out post hoc analy­sis on a tiny sub­group of pa­tients in an ef­fort to prove its drug isn’t worth­less. A tiny group of 18 Alzheimer’s pa­tients with di­a­betes demon­strat­ed a 6.1 point ben­e­fit on ADAS-cog rel­a­tive to the place­bo group. They claimed that was sta­tis­ti­cal­ly sig­nif­i­cant, though skep­tics are like­ly to hoot.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.